Pharmacist Digest

STAT+: AstraZeneca picks up rare-disease focused Amolyt Pharma in $1 billion deal

STAT

MARCH 14, 2024

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial. AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

STAT+: As targeted radiation field heats up, AstraZeneca to pick up Fusion Pharmaceuticals in $2 billion deal

STAT

MARCH 19, 2024

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Drug Development

STAT+: Federal judge rules against AstraZeneca in lawsuit challenging Medicare drug price negotiation

STAT

MARCH 1, 2024

WASHINGTON — A federal judge in Delaware on Friday ruled against AstraZeneca in a case challenging the constitutionality of Medicare’s new drug price negotiation program. Colm Connolly, chief judge of the U.S. District Court of Delaware, ruled against the company on all its major arguments.

Drug Pricing

FDA approves AstraZeneca, Ionis treatment for rare nerve disease

STAT

DECEMBER 21, 2023

The drug, from partners AstraZeneca and Ionis Pharmaceuticals, is a monthly injection for a genetic disorder called ATTR-PN, in which a buildup of toxic bodily proteins progressively damages patients’ peripheral nerves.

Drug Development

AstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?

PharmaVoice

NOVEMBER 16, 2023

conducted a study with AstraZeneca showing the alarming extent to which immunocompromised patients are burdened with COVID-19. Paul Moss, a hematology expert in the U.K.,

STAT+: AstraZeneca sues Arkansas over the role of pharmacies in a federal discount drug program

STAT

MARCH 27, 2024

AstraZeneca filed a lawsuit seeking to block an Arkansas law that requires the company to ship its medicines to any pharmacy working with hospitals participating in a controversial federal discount program. As a result, AstraZeneca argued the law is illegal because it is preempted by federal law and also violates the U.S. Constitution.

Hospitals

Hospitals Pharmaceutical Companies Pharmaceutical Companies

STAT+: Breast cancer drug from AstraZeneca, Daiichi hits goal in late-stage trial

STAT

SEPTEMBER 22, 2023

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

Chemotherapy

STAT+: Data on AstraZeneca cancer drug allay safety concerns but treatment still faces questions

STAT

OCTOBER 23, 2023

MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs and drabs that have come out about its performance — have been dogging the company for months. Patients were randomized to either receive chemotherapy or Dato-DXd, which AstraZeneca is developing with Daiichi Sankyo.

Chemotherapy

Chemotherapy Drug Development

AstraZeneca, maker of FluMist, seeks to allow at-home administration of vaccine

STAT

OCTOBER 24, 2023

AstraZeneca, which makes the vaccine FluMist, announced Tuesday it has submitted to the Food and Drug Administration a supplemental biologics license application that would allow for self-administration of the vaccine by people ages 18 through 49, and would allow people 18 and older to give the vaccine to eligible children.

Vaccines

AstraZeneca withdraws COVID-19 vaccine, citing declining demand

BioPharma Dive

MAY 8, 2024

The move ends a turbulent saga for AstraZeneca, which successfully developed a coronavirus shot but struggled to sell it amid competition and the emergence of rare but serious side effects.

Vaccines

AstraZeneca withdraws Covid-19 vaccine worldwide, citing surplus of newer vaccines

The Guardian - Pharmaceutical Industry

MAY 7, 2024

Pharmaceutical company says newer shots led to decline in demand for AstraZeneca vaccine, which is no longer being manufactured or supplied AstraZeneca has begun the worldwide withdrawal of its Covid-19 vaccine due to a “surplus of available updated vaccines” that target new variants of the virus.

Vaccines

Vaccines Pharmaceutical Companies Pharmaceutical Companies

STAT+: As Medicare drug pricing negotiations begin, AstraZeneca stays mum on government’s offer

STAT

FEBRUARY 8, 2024

On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga.

Drug Pricing

Drug Pricing Diabetes

AstraZeneca to withdraw Covid-19 vaccine globally

Pharmaceutical Technology

MAY 8, 2024

AstraZeneca has begun the global withdrawal of its Covid-19 vaccine Vaxzevria, citing a surplus of updated vaccines.

Vaccines

AstraZeneca concludes equity investment in Cellectis

Pharmaceutical Technology

MAY 7, 2024

AstraZeneca has concluded an equity investment in clinical-stage biotechnology company Cellectis following a deal signed in November 2023.

AstraZeneca withdraws COVID-19 vaccine Vaxzevria

Pharmafile

MAY 9, 2024

UK-based pharmaceutical company AstraZeneca has announced that is it voluntarily withdrawing its COVID-19 vaccine Vaxzevria due to a drop in global demand. The withdrawal also comes after AstraZeneca admitted in court documents that the vaccine can cause thrombosis with thrombocytopenia syndrome (TTS).

Vaccines

Vaccines Documentation Pharmaceutical Companies Pharmaceutical Companies

STAT+: In lung cancer, J&J data amount to latest salvo against AstraZeneca

STAT

OCTOBER 23, 2023

MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson and AstraZeneca — to gain an edge in the market for targeted lung cancer treatments. A primetime presentation here Monday amounted to the latest salvo.

Drug Development

AstraZeneca is third member to leave PhRMA in five months

STAT

MAY 16, 2023

WASHINGTON — AstraZeneca has decided to leave the brand drug lobbying powerhouse PhRMA halfway through the year, the organization said. The exit is the group’s third in five months, as AbbVie exited PhRMA in December and Teva Pharmaceuticals left in February. Read the rest…

Drug Pricing

AstraZeneca admits Covid-19 vaccine may cause blood clots in “very rare” cases

Pharmaceutical Technology

MAY 1, 2024

AstraZeneca has maintained that while the vaccine may, in “very rare” cases, cause TTS, the casual mechanism for this effect remains unknown.

Vaccines

Angle signs AstraZeneca deal to develop prostate cancer assay

Pharmaceutical Technology

MAY 3, 2024

UK liquid biopsy company, Angle, has agreed a supplier agreement with AstraZeneca to develop a Parsotix-based Androgen Receptor (AR) assay for use in prostate cancer studies.

STAT+: Pharmalittle: We’re reading about an AstraZeneca deal, a WHO pandemic pact, and more

STAT

MARCH 19, 2024

… AstraZeneca agreed to acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the blooming area of targeted radiation therapies for cancer , STAT writes. Meanwhile, we are once again foraging for items of interest, some of which we have collected below. Just keep scrolling down.

STAT+: AstraZeneca is fined by South Korea for an anticompetitive deal over a cancer drug

STAT

OCTOBER 13, 2022

South Korea’s anti-trust regulator has fined AstraZeneca and a local generic drugmaker a total of $1.8 In this case, the local company, Alvogen, reportedly agreed to suspend plans to release a version of an AstraZeneca medication called Zoladex, which is used to combat prostate and breast cancer.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies

STAT+: AstraZeneca buys early-stage gene therapies from Pfizer in boon for struggling field

STAT

JULY 28, 2023

AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

STAT+: AstraZeneca shares fall after lung cancer drug underwhelms in trial

STAT

JULY 3, 2023

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading. But investors had been hoping for a clearer signal of benefit.

Chemotherapy

Chemotherapy Drug Development

AstraZeneca to acquire Icosavax

World Pharma News

DECEMBER 12, 2023

AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc. The proposed acquisition will build on AstraZeneca's expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca's Vaccines & Immune Therapies late-stage pipeline with Icosavax's lead investigational vaccine candidate, IVX-A12.

Vaccines

Vaccines Immunity Immunization

ANGLE signs commercial agreement with AstraZeneca

Pharmafile

APRIL 26, 2024

ANGLE has announced that it has signed a supplier agreement with AstraZeneca for the development and validation of a methodology which will leverage ANGLE’s existing DNA damage response (DDR) assay for the detection of micronuclei in circulating tumour cells (CTCs) as a measure of DDR.

Pfizer, AstraZeneca to invest nearly $1 bn in France

Express Pharma

MAY 12, 2024

Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year’s annual ‘Choose France’ business summit. 1 = 0.9286 euros) Edits made by EP News Bureau The post Pfizer, AstraZeneca to invest nearly $1 bn in France appeared first on Express Pharma.

AstraZeneca shares positive interim results from phase 3 lymphoma trial

Pharmafile

MAY 3, 2024

AstraZeneca has announced positive high-level results from an interim analysis of the ECHO phase 3 trial, which assessed Calquence (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, for the treatment of mantle cell lymphoma (MCL).

AstraZeneca buys rare disease firm Amolyt for $1.05bn

pharmaphorum

MARCH 14, 2024

AstraZeneca adds a late-stage rare disease therapy to its pipeline, buying Amolyt Pharma and hypoparathyroidism drug eneboparatide for $800 million upfront.

UK Chancellor trumpets £650m AstraZeneca investment

pharmaphorum

MARCH 6, 2024

A £650 million investment package by AstraZeneca in the UK has been held up by Chancellor Jeremy Hunt as a “vote of confidence” in the country’s life sciences sector.

Packaging

Packaging Vaccines

AstraZeneca bets on new cancer treatments with $2 billion Fusion Pharma purchase

Express Pharma

MARCH 19, 2024

The deal is AstraZeneca’s second this month after it agreed last week to buy Amolyt Pharma for $1.05 The deal is AstraZeneca’s second this month after it agreed last week to buy Amolyt Pharma for $1.05 The deal is AstraZeneca’s second this month after it agreed last week to buy Amolyt Pharma for $1.05

Chemotherapy

New patent for Astrazeneca drug CALQUENCE

Drug Patent Watch

OCTOBER 30, 2023

Annual Drug Patent Expirations for CALQUENCE Calquence is a drug marketed by Astrazeneca and is included in two NDAs. There are eight patents protecting… The post New patent for Astrazeneca drug CALQUENCE appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

STAT+: FDA warns AstraZeneca over misleading promotional materials for a COPD drug

STAT

AUGUST 15, 2023

The Food and Drug Administration scolded AstraZeneca for making misleading claims about the effectiveness of a key medicine used treat chronic obstructive pulmonary disease. In an Aug.

AstraZeneca India gets dual CDSCO approval for Trastuzumab deruxtecan

Express Pharma

MARCH 26, 2024

AstraZeneca Pharma India has received permission to import for sale and distribution of Trastuzumab deruxtecan lyophilised powder for concentrate for solution for infusion 100mg from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India for two additional indications.

Chemotherapy

AstraZeneca to acquire Gracell Biotechnologies

Express Pharma

DECEMBER 26, 2023

AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies, a global clinical-stage biopharma company developing innovative cell therapies for the treatment of cancer and autoimmune diseases. Gracell will operate as a wholly owned subsidiary of AstraZeneca, with operations in China and the US.

Immunity

Immunity Immunization

New patent for Astrazeneca drug CALQUENCE

Drug Patent Watch

OCTOBER 31, 2023

Annual Drug Patent Expirations for CALQUENCE Calquence is a drug marketed by Astrazeneca and is included in two NDAs. There are eight patents protecting… The post New patent for Astrazeneca drug CALQUENCE appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

Case Study: MHRA and AstraZeneca

pharmaphorum

MARCH 28, 2024

Explore the case study on MHRA and AstraZeneca's camizestrant, a Selective Estrogen Receptor Degrader (SERD) for breast cancer treatment. Learn about the regulatory journey and success of this innovative therapy.

AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline

World Pharma News

MARCH 14, 2024

AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases.

STAT+: Pharmalittle: Is Pascal Soriot leaving AstraZeneca? PBMs try to counter congressional crackdown

STAT

SEPTEMBER 12, 2023

AstraZeneca appeared to play down speculation about the future of its chief executive officer after its shares fell more than 4% on Monday following a U.K. Among the obesity drugs in development that are taking the same approach of activating hormone receptors, a little over half of them are targeting a combination of different hormones.

AstraZeneca and Cellectis to collaborate for cell therapy and genomic medicine development

Pharmafile

NOVEMBER 1, 2023

AstraZeneca has announced a collaboration and investment agreement with Cellectis for the development of next generation cell and gene therapeutics (CGTs) in areas such as oncology, immunology and rare diseases.

STAT+: Patient groups balk at former AstraZeneca official negotiating U.K.-India free trade deal

STAT

MARCH 21, 2023

Director for Policy & Trade Negotiations, may be compromised because he previously spent nearly three decades in different positions at AstraZeneca. Now, the groups are upset that the involvement of Harjinder Kang, the U.K. Continue to STAT+ to read the full story…

Generic Medicine

Generic Medicine Pharmaceutical Companies Pharmaceutical Companies

AstraZeneca India, Mankind Pharma sign pact to distribute asthma medicine in India

Express Pharma

MARCH 11, 2024

AstraZeneca Pharma India and Mankind Pharma entered into an agreement for exclusive distribution of AstraZeneca’s budesonide and formoterol fumarate dihydrate ( inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India.

New patent for Astrazeneca drug TAGRISSO

Drug Patent Watch

APRIL 14, 2024

Annual Drug Patent Expirations for TAGRISSO Tagrisso is a drug marketed by Astrazeneca and is included in one NDA. It is available from one supplier. There are four patents protecting… Source

AstraZeneca to acquire Fusion for approximately $2bn

Pharmafile

MARCH 19, 2024

AstraZeneca has announced that it has entered into a definitive agreement to acquire Fusion Pharmaceuticals for an approximate $2bn. Fusion Pharmaceuticals has a […] The post AstraZeneca to acquire Fusion for approximately $2bn appeared first on Pharmafile.

Chemotherapy

AstraZeneca Gains FDA Nod for Ultomiris, a Treatment for Managing NMOSD

PharmaTech

MARCH 29, 2024

FDA has approved AstraZeneca's Ultomiris, marking the first and only long-acting C5 complement inhibitor for patients with NMOSD.

STAT+: AstraZeneca picks up rare-disease focused Amolyt Pharma in $1 billion deal

STAT+: As targeted radiation field heats up, AstraZeneca to pick up Fusion Pharmaceuticals in $2 billion deal

Trending Sources

STAT+: Federal judge rules against AstraZeneca in lawsuit challenging Medicare drug price negotiation

FDA approves AstraZeneca, Ionis treatment for rare nerve disease

AstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?

STAT+: AstraZeneca sues Arkansas over the role of pharmacies in a federal discount drug program

STAT+: Breast cancer drug from AstraZeneca, Daiichi hits goal in late-stage trial

STAT+: Data on AstraZeneca cancer drug allay safety concerns but treatment still faces questions

AstraZeneca, maker of FluMist, seeks to allow at-home administration of vaccine

AstraZeneca withdraws COVID-19 vaccine, citing declining demand

AstraZeneca withdraws Covid-19 vaccine worldwide, citing surplus of newer vaccines

STAT+: As Medicare drug pricing negotiations begin, AstraZeneca stays mum on government’s offer

AstraZeneca to withdraw Covid-19 vaccine globally

AstraZeneca concludes equity investment in Cellectis

AstraZeneca withdraws COVID-19 vaccine Vaxzevria

STAT+: In lung cancer, J&J data amount to latest salvo against AstraZeneca

AstraZeneca is third member to leave PhRMA in five months

AstraZeneca admits Covid-19 vaccine may cause blood clots in “very rare” cases

Angle signs AstraZeneca deal to develop prostate cancer assay

STAT+: Pharmalittle: We’re reading about an AstraZeneca deal, a WHO pandemic pact, and more

STAT+: AstraZeneca is fined by South Korea for an anticompetitive deal over a cancer drug

STAT+: AstraZeneca buys early-stage gene therapies from Pfizer in boon for struggling field

STAT+: AstraZeneca shares fall after lung cancer drug underwhelms in trial

AstraZeneca to acquire Icosavax

ANGLE signs commercial agreement with AstraZeneca

Pfizer, AstraZeneca to invest nearly $1 bn in France

AstraZeneca shares positive interim results from phase 3 lymphoma trial

AstraZeneca buys rare disease firm Amolyt for $1.05bn

UK Chancellor trumpets £650m AstraZeneca investment

AstraZeneca bets on new cancer treatments with $2 billion Fusion Pharma purchase

New patent for Astrazeneca drug CALQUENCE

STAT+: FDA warns AstraZeneca over misleading promotional materials for a COPD drug

AstraZeneca India gets dual CDSCO approval for Trastuzumab deruxtecan

AstraZeneca to acquire Gracell Biotechnologies

New patent for Astrazeneca drug CALQUENCE

Case Study: MHRA and AstraZeneca

AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline

STAT+: Pharmalittle: Is Pascal Soriot leaving AstraZeneca? PBMs try to counter congressional crackdown

AstraZeneca and Cellectis to collaborate for cell therapy and genomic medicine development

STAT+: Patient groups balk at former AstraZeneca official negotiating U.K.-India free trade deal

AstraZeneca India, Mankind Pharma sign pact to distribute asthma medicine in India

New patent for Astrazeneca drug TAGRISSO

AstraZeneca to acquire Fusion for approximately $2bn

AstraZeneca Gains FDA Nod for Ultomiris, a Treatment for Managing NMOSD

Stay Connected